MedImmune Stands to Get Merck Money

MedImmune, which struck a deal with GlaxoSmithKline (GSK) eight years ago to develop a cervical cancer vaccine, may get more mileage out of the deal through a partnership GSK has with fellow drugmaker Merck. The Gaithersburg-based company says it has amended its agreement with GSK and could get royalty and milestone payments from Merck from future sales of a human papillomavirus vaccine (HPV) Merck has in development. GSK gave Merck a sublicense to MedImmune's patent rights for its own HPV program.

Washington Business Journal (http://www.bizjournals.com/washington/stories/2005/01/31/daily21.html)